Welcome to Market Research Explore

Explore Market Research

Latest market research, industry analysis and market trend reports

Global Diabetes Therapeutics Market 2018-2025

The global diabetes Therapeutics market is estimated to be USD XX million in 2017 and the market is estimated to grow at a CAGR of XX% in the forecasted period to reach a market value of USD XX million by 2025. Growing focus on regenerative therapies, presence of strong product pipeline portfolio, companies focus on oral insulin therapies, and growing technological advancements across the world which are helping in R&D are some of the key trends in the global diabetes therapeutics market. Market Dynamics Consumer’s preference on self-medication for the treatment of diabetes, growing demand for biologics, presence of high unmet needs, and large scope for Dimethyl disulphide (DMD’s) are some of the key factors driving the growth of the diabetes therapeutics market. Growing complexity in storage and distribution of the insulin, highly unpredictable nature of drugs in the outcome on humans, raising concerns in the scientific communities and gap in the national level diabetes management plans are some of the key challenges for the growth of the diabetes therapeutics market. Segmentation by Disease Type The diabetes therapeutics market by disease type has been segmented into type 1 diabetes, type 2 diabetes, and Gestational diabetes. Type 2 diabetes is one of the most prevalent types of diabetes across the world. The majority of the population suffering with diabetes is the older population, though it is estimated the market is growing at a higher rate in younger population. By marketed products, Actos, Januvia, Lantus, and Lantus Solostar have the highest revenue share in United States. The gestational diabetes market is growing at a highest growth rate in the forecasted period. Segmentation by Geography North America dominates the global diabetes therapeutics market share in 2017 and the region is estimated to dominate the global market by the end of the forecasted period 2025. Growing prevalence of diabetes in United States and potential opportunities for the development of the high unmet needs, growing demand for safer and efficient drug are the major factors for the market to dominate by the end of forecasted period. The prevalence of type II diabetes in Europe is increasing due to changing lifestyle and changing food consumption preferences. Competitive Landscape The global diabetes therapeutics market is a consolidated market with 90% of the market being dominated by top 10 companies in the industry. Novo Nordisk, Sanofi, Eli Lilly and Merck are some of the major companies in the diabetes therapeutics industry with these four companies occupying more than 70% of the market share in 2017. Merck is estimated to significantly loose it’s more than half of market share by the end of the forecasted period 2025 with Boehringer Ingelheim gaining the large market share. Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Sanofi with have the largest market share in 2025 with these four companies occupying 72.6% market share. Scope of the Report Segmentation by Marketed Drugs Lantus (Sanofi) Janumet (Merck) Humalog (Eli Lilly) Victoza (Novo Nordisk) Trulicity (Eli Lilly) Januvia (Merck) Levemir (Novo Nordisk) Trajenta (Boehringer Ingelheim) Novolog (Novo Nordisk) Segmentation by Diseases Type 1 diabetes Type 2 diabetes Gestational diabetes Segmentation by Drug Class Insulin Therapies Non-Insulin Therapies The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles. Why Purchase the Report? • Visualize the composition of the global diabetes therapeutics market with clear distinction between each design type and usage type. • Identify commercial opportunities in the global diabetes therapeutics market analysing trends and co-development deals. • Excel data sheet with thousands of data points of the global diabetes therapeutics market. • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. • Product mapping in excel for the key products of all major market players Target Audience: • Equipment Suppliers/ Buyers • Service Providers/ Buyers • Industry Investors/Investment Bankers • Education & Research Institutes • Research Professionals • Emerging Companies • Manufacturers

1: Methodology and Scope 1.1 Research Methodology 1.2 Scope of the report 2: Industry Analysis 2.1 Market Drivers 2.2 Market Restraints 2.3 Porters Five Forces 3. Market Overview 3.1 Epidemiology Analysis 3.2 Clinical Trial Analysis 4. Product Pipeline Analysis 5. Segmentation by Marketed Drugs 5.1 Lantus (Sanofi) 5.2 Janumet (Merck) 5.3 Humalog (Eli Lilly) 5.4 Victoza (Novo Nordisk) 5.5 Trulicity (Eli Lilly) 5.6 Januvia (Merck) 5.7 Levemir (Novo Nordisk) 5.8 Trajenta (Boehringer Ingelheim) 5.9 Novolog (Novo Nordisk) 6. Segmentation by Diseases 6.1 Type 1 diabetes 6.2 Type 2 diabetes 6.3 Gestational diabetes 7. Segmentation by Drug Class 7.1 Insulin Therapies 7.2 Non-Insulin Therapies 8. Segmentation by Geography 8.1 North America 8.1.1 United States 8.1.2 Canada 8.1.3 Mexico 8.1.4 Rest of North America 8.2 Europe 8.2.1 United Kingdom 8.2.2 Germany 8.2.3 Spain 8.2.4 France 8.2.5 Rest of Europe 8.3 Asia-Pacific 8.3.1 China 8.3.2 Japan 8.3.3 India 8.3.4 Australia 8.3.5 Rest of Asia-Pacific 8.4 South America 8.4.1 Brazil 8.4.2 Argentina 8.4.3 Rest of South America 8.5 Rest of the World 9. Competitive Landscape 9.1 Market Player Analysis 9.2 Key Strategies Adopted by Major companies 10. Company Profiles 10.1 Novo Nordisk 10.2 Merck 10.3 AstraZeneca 10.4 Eli Lilly 10.5 Sanofi 10.6 Boehringer Ingelheim 10.7 Johnson and Johnson 10.8 GSK 10.9 Takeda Pharmaceutical 10.10 Bayer 11. Appendix 11.1 Disclaimer 11.2 Contact Us

  Payment Mode
Single User 2980
Corporate User 5600

  About this Report
Category Healthcare
Published on 1/22/2019
Number of Pages 178
Over all Rating
"Rating is based on 97 reviews"